This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Long-term treatment of immunosuppressive agent have been proved to induce hypertension. The relative efficacy of mycophenolate mofetil (MMF) on blood pressure (BP) is not well known. Identifying the performance of this drug will help to reduce the incidence of the adverse reactions.
Methods: We systematically searched PubMed, MEDLINE, EMBASE, and the Cochrane Library for relevant studies published up to December, 2017. We compared blood pressure levels before and after the MMF treatment including systolic blood pressure and diastolic blood pressure. We used the Newcastle Ottawa scale for the assessment of the quality of studies. Analysis was performed using the statistical software Review Manager Version 5.0 and STATA 14.0.
Result: We retrieved 6 studies with 208 patients. The data extracted were systolic BP (SBP) and diastolic BP (DBP). Study quality was assessed using the method of Jadad, and data were synthesized using a random-effects model and weight mean difference. MMF caused a small reduce in DBP (0.79mmHg, 95% CI, 0.03 to 1.55, P=0.043), with no obvious effect on SBP (0.12mmHg, 95%CI -0.41 to 0.64). In meta-regression, country (china vs. other country), duration of follow-up, percentage of men, and mean age of study participants were proved to be not the contributing factors.
Conclusion: The MMF treatment can slightly reduce DBP, but not affect the SBP, which indicated the cardiovascular safety of this immunosuppressive agent.
Keywords
blood pressure, meta-analysis, mycophenolate mofetil
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 17 Oct, 2019
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cardiothoracic Surgery
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research article
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 17 Oct, 2019
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cardiothoracic Surgery
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Long-term treatment of immunosuppressive agent have been proved to induce hypertension. The relative efficacy of mycophenolate mofetil (MMF) on blood pressure (BP) is not well known. Identifying the performance of this drug will help to reduce the incidence of the adverse reactions.
Methods: We systematically searched PubMed, MEDLINE, EMBASE, and the Cochrane Library for relevant studies published up to December, 2017. We compared blood pressure levels before and after the MMF treatment including systolic blood pressure and diastolic blood pressure. We used the Newcastle Ottawa scale for the assessment of the quality of studies. Analysis was performed using the statistical software Review Manager Version 5.0 and STATA 14.0.
Result: We retrieved 6 studies with 208 patients. The data extracted were systolic BP (SBP) and diastolic BP (DBP). Study quality was assessed using the method of Jadad, and data were synthesized using a random-effects model and weight mean difference. MMF caused a small reduce in DBP (0.79mmHg, 95% CI, 0.03 to 1.55, P=0.043), with no obvious effect on SBP (0.12mmHg, 95%CI -0.41 to 0.64). In meta-regression, country (china vs. other country), duration of follow-up, percentage of men, and mean age of study participants were proved to be not the contributing factors.
Conclusion: The MMF treatment can slightly reduce DBP, but not affect the SBP, which indicated the cardiovascular safety of this immunosuppressive agent.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...